X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs ALEMBIC PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA ALEMBIC PHARMA ELDER PHARMA/
ALEMBIC PHARMA
 
P/E (TTM) x -0.2 23.2 - View Chart
P/BV x 0.1 6.1 1.7% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 ELDER PHARMA   ALEMBIC PHARMA
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
ALEMBIC PHARMA
Mar-16
ELDER PHARMA/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs380792 48.0%   
Low Rs188443 42.4%   
Sales per share (Unadj.) Rs491.2167.0 294.1%  
Earnings per share (Unadj.) Rs-3.238.2 -8.3%  
Cash flow per share (Unadj.) Rs14.442.0 34.3%  
Dividends per share (Unadj.) Rs04.00 0.0%  
Dividend yield (eoy) %00.6 0.0%  
Book value per share (Unadj.) Rs376.584.9 443.5%  
Shares outstanding (eoy) m20.54188.52 10.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.63.7 15.6%   
Avg P/E ratio x-89.316.2 -551.8%  
P/CF ratio (eoy) x19.714.7 134.1%  
Price / Book Value ratio x0.87.3 10.4%  
Dividend payout %010.5 0.0%   
Avg Mkt Cap Rs m5,833116,383 5.0%   
No. of employees `000NANA-   
Total wages/salary Rs m2,1794,214 51.7%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m10,08931,487 32.0%  
Other income Rs m25755 465.7%   
Total revenues Rs m10,34631,542 32.8%   
Gross profit Rs m-79210,060 -7.9%  
Depreciation Rs m361722 50.0%   
Interest Rs m2,75637 7,489.9%   
Profit before tax Rs m-3,6539,356 -39.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m1252,160 5.8%   
Profit after tax Rs m-657,194 -0.9%  
Gross profit margin %-7.831.9 -24.6%  
Effective tax rate %-3.423.1 -14.8%   
Net profit margin %-0.622.8 -2.8%  
BALANCE SHEET DATA
Current assets Rs m9,24015,066 61.3%   
Current liabilities Rs m9,9987,674 130.3%   
Net working cap to sales %-7.523.5 -32.0%  
Current ratio x0.92.0 47.1%  
Inventory Days Days4667 69.2%  
Debtors Days Days6041 147.5%  
Net fixed assets Rs m10,1248,237 122.9%   
Share capital Rs m206377 54.6%   
"Free" reserves Rs m5,58215,416 36.2%   
Net worth Rs m7,73416,005 48.3%   
Long term debt Rs m4,8890-   
Total assets Rs m22,88224,594 93.0%  
Interest coverage x-0.3255.2 -0.1%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.41.3 34.4%   
Return on assets %11.829.4 40.0%  
Return on equity %-0.844.9 -1.9%  
Return on capital %22.358.7 38.0%  
Exports to sales %3.055.7 5.5%   
Imports to sales %0.410.4 4.1%   
Exports (fob) Rs m30717,551 1.7%   
Imports (cif) Rs m433,283 1.3%   
Fx inflow Rs m30717,811 1.7%   
Fx outflow Rs m1255,318 2.4%   
Net fx Rs m18112,493 1.5%   
CASH FLOW
From Operations Rs m11,7549,304 126.3%  
From Investments Rs m-561-3,105 18.1%  
From Financial Activity Rs m-6,762-1,959 345.1%  
Net Cashflow Rs m4,4324,240 104.5%  

Share Holding

Indian Promoters % 39.6 74.1 53.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 2.9 258.6%  
FIIs % 16.8 9.1 184.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 13.9 259.7%  
Shareholders   16,479 49,328 33.4%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   MERCK LTD  STERLING BIOTECH  ASTRAZENECA PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare ELDER PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Cuts Losses; TCS Up 3%(Closing)

After opening the day in red, share markets in India witnessed volatile trading activity throughout the day but clawed back some gains in the final hours of the trading window.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 8-QTR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS